cymabay
therapeutics
announces
oral
presentation
results
enhance
global
phase
study
evaluating
seladelpar
primary
biliary
cholangitis
liver
newark
globe
newswire
cymabay
therapeutics
nasdaq
cbay
biopharmaceutical
company
focused
developing
providing
access
innovative
therapies
patients
liver
chronic
diseases
today
announced
presentation
highlighting
results
enhance
phase
study
seladelpar
patients
primary
biliary
cholangitis
pbc
delivered
liver
meeting
digital
tlmdx
american
association
study
liver
diseases
aasld
held
online
november
oral
presentation
titled
enhance
safety
efficacy
seladelpar
patients
primary
biliary
cholangitis
pbc
phase
international
randomized
study
delivered
professor
gideon
hirschfield
md
university
toronto
sujal
shah
ceo
cymabay
therapeutics
commented
honored
presenting
data
development
seladelpar
patients
pbc
year
aasld
liver
meeting
look
forward
sharing
additional
results
enhance
study
focus
initiating
new
global
phase
study
support
registration
seladelpar
pbc
believe
opportunity
present
session
liver
fourth
consecutive
year
remarkable
achievement
reflection
potential
seladelpar
address
significant
unmet
needs
remain
patients
pbc
remain
committed
patients
families
grateful
participation
oral
presentation
presentation
november
pm
est
enhance
safety
efficacy
seladelpar
patients
primary
biliary
cholangitis
pbc
phase
international
randomized
study
gideon
hirschfield
kris
kowdley
mitchell
shiffman
arun
khazanchi
ehud
zigmond
eric
lawitz
dan
pratt
richard
aspinall
lisa
forman
stuart
gordon
aliya
gulamhusein
alma
laura
cynthia
levy
stephen
ryder
carmen
stanca
carlos
bresky
ruiz
maria
sarai
gonzalez
huezo
jeong
heo
barbara
leggett
gerald
minuk
mangesh
pagadala
david
pound
karina
raikhelson
marina
silveira
mark
swain
kidist
yimam
ziad
younes
eli
zuckerman
christophe
corpechot
stephen
harrison
pietro
invernizzi
frederik
nevens
douglas
thorburn
christopher
bowlus
george
dalekos
david
jones
andreas
kremer
albert
pares
john
vierling
pol
boudes
monika
varga
yun
choi
charles
mcwherter
alexandra
steinberg
marlyn
mayo
congress
attendees
visit
cymabay
throughout
meeting
cymabay
booth
exhibitors
section
tlmdx
homepage
full
list
presentations
found
liver
meeting
digital
website
presentations
also
made
available
cymabay
website
pbc
pbc
rare
chronic
inflammatory
liver
disease
primarily
affecting
women
age
pbc
characterized
impaired
bile
flow
known
cholestasis
accumulation
toxic
bile
acids
liver
leading
inflammation
destruction
bile
ducts
within
liver
causing
increased
levels
alkaline
phosphatase
alp
total
bilirubin
common
early
symptoms
pbc
itching
pruritus
fatigue
debilitating
patients
progression
pbc
associated
increased
risk
liver
cancer
mortality
seladelpar
seladelpar
potent
selective
orally
active
pparÎ´
agonist
development
treatment
liver
diseases
primary
biliary
cholangitis
pbc
nonalcoholic
steatohepatitis
nash
pbc
seladelpar
received
orphan
designation
us
food
drug
administration
fda
european
medicine
agency
ema
seladelpar
also
received
breakthrough
therapy
designation
fda
early
stage
pbc
priority
medicine
status
ema
cymabay
cymabay
therapeutics
biopharmaceutical
company
focused
developing
therapies
liver
chronic
diseases
high
unmet
medical
need
cautionary
statements
statements
press
release
regarding
potential
seladelpar
treat
nash
pbc
potential
benefits
patients
cymabay
expectations
plans
regarding
current
future
clinical
trials
cymabay
ability
fund
current
planned
clinical
trials
forward
looking
statements
subject
risks
uncertainties
actual
results
timing
events
regarding
development
seladelpar
could
differ
materially
anticipated
statements
result
risks
uncertainties
include
without
limitation
risks
related
success
cost
timing
cymabay
product
development
activities
including
clinical
trials
effects
observed
trials
date
may
repeated
future
delays
inability
obtain
maintain
regulatory
approval
cymabay
product
candidates
united
states
worldwide
ability
cymabay
obtain
sufficient
financing
complete
development
regulatory
approval
commercialization
product
candidates
united
states
worldwide
potentially
restart
clinical
trials
additional
risks
relating
cymabay
contained
cymabay
filings
securities
exchange
commission
including
without
limitation
recent
annual
report
form
documents
subsequently
filed
furnished
securities
exchange
commission
cymabay
disclaims
obligation
update
statements
except
required
law
additional
information
cymabay
visit
public
relations
contact
glenn
silver
partners
investor
relations
contact
hans
vitzthum
lifesci
advisors
llc
hans
